AI Article Synopsis
- Serum (1→3) beta-D-glucan (BG) testing is an important tool for diagnosing systemic fungal infections, but it can produce false-positive results when patients receive intravenous immunoglobulins (IVIG).
- In a study, the BG levels in seven different IVIG preparations were tested, showing significant variability and suggesting possible contamination during production.
- The findings indicated that IVIG administration resulted in a false-positive rate of 9.8%, decreasing the positive predictive value of BG tests to 37.5%, highlighting the need for careful interpretation of BG results in patients receiving IVIG.
Article Abstract
Serum (1→3) beta-D-glucan (BG) measurement is a useful test for systemic mycoses, and often used. On the other hand, various factors, including administration of intravenous immunoglobulins (IVIG) may cause false-positives. In the present study, we measured BG concentration of seven IVIG preparations with three lots respectively. BG levels varied with individual IVIG preparations (<3.0 - >300 pg/mL), and contamination from manufacturing processes was suspected. With serum BG concentration of clinical specimens obtained in Niigata University Medical & Dental Hospital, the difference between before and after administration of IVIG were calculated. The false-positive rate of BG due to IVIG administration was 9.8 %, and the positive predective value was reduced to 37.5%. Above all, administration of IVIG can complicate the BG test's interpretation, and caution is required.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Two Patients with Therapy-Resistant Pemphigus Vulgaris and Severe Underlying Disease Showing Good Response to a New IVIg Preparation.
Dermatol Ther (Heidelb)
January 2025
Department of Dermatology, University Hospital Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Germany.
Pemphigus vulgaris is a severe and often therapy-resistant bullous autoimmune disease. Standard therapy with steroids often administered together with another immunosuppressant does not respond in all patients or may not be a good therapeutic option in patients with severe underlying diseases. Intravenous immunoglobulins (IVIgs) represent a treatment alternative, often showing a rapid response which allows one to reduce concomitant immunosuppression.
View Article and Find Full Text PDFGuillain-Barré syndrome.
Nat Rev Dis Primers
December 2024
Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Guillain-Barré syndrome (GBS) is a rare immune-mediated polyradiculoneuropathy. Patients typically develop rapidly progressive weakness and sensory deficits that can result in complete paralysis requiring mechanical ventilation. GBS is usually a monophasic disease in which an aberrant immune response to an infection or other trigger damages the peripheral nerves.
View Article and Find Full Text PDFOsimertinib-Induced Toxic Epidermal Necrolysis - A Case Report.
Pril (Makedon Akad Nauk Umet Odd Med Nauki)
November 2024
Faculty of Medicine, University Clinic of Radiotherapy and Oncology, Skopje, Macedonia.
Purpose: To investigate the rare side effects of Osimertinib in a case of toxic epidermal necrosis.
Case Presentation: We report on a case of a 44-year old woman with lung adenocarcinoma harboring an EGFR-sensitizing mutation who was treated with Osimertinib as the second-line treatment. Ten days after Osimertinib initiation, a diffuse erythematous rash rapidly spread over the patient's trunk along with vesicles and purpuric macules; furthermore, she developed erythema and exfoliation on the face and trunk and severe mucositis.
Safety and efficacy of a novel mini-pool intravenous immunoglobulin therapy in children with primary immunodeficiency.
Vox Sang
December 2024
Shabrawishi Hospital Blood Transfusion Center, Finni Square, Giza, Egypt.
Article Synopsis
- Intravenous polyvalent immunoglobulins (IVIG) are vital for patients with primary immunodeficiency disorders (PIDs) but access can be limited in lower middle-income countries; the WHO suggests local production using new technologies.
- A clinical study compared the safety and effectiveness of mini-pool IVIG (MP-IVIG) to standard IVIG (STD-IVIG) in 21 pediatric PID patients, finding that both treatments reduced severe bacterial infections and hospitalizations.
- Results showed that MP-IVIG did not present safety issues and was as effective as STD-IVIG, although findings should be interpreted cautiously due to the small sample size.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!